Benjamin Weide

TL;DR: Results of nine studies that occurred during the last four decades were reviewed and evidence is that incisional biopsies were not associated with an unfavorable prognosis for melanoma patients.

TL;DR: Intralesional therapy using the immunocytokine L19–IL2 elicited a high rate of clinical and systemic immune responses in patients with stage III melanoma and report their observation of favorable distant metastasis-free and overall survival in these patients after treatment.

TL;DR: The results show that unlimited amounts of cRNA representing tumor's transcriptome could be obtained and that this cRNA was a reliable source of a large variety of tumor antigens.

TL;DR: This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease to detect relapse following surgical or adjuvant treatment.

TL;DR: Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate, suggesting an important predictive role of baseline CD8 EM1 cells and changes inCD8 cells for clinical response of ipilimumab.